Paul-Ehrlich-Institut

COVID-19 Vac­cines

Proof of complete vaccination protection

For proof of complete vaccine protection against SARS-CoV-2 coronavirus, the underlying protective vaccination must be with one or more vaccines. The applicable requirements for this can be found here:

Proof of Vaccination as Defined in the COVID-19 Protective Measures Exemption Directive and the Directive on Coronavirus Entry Regulations

List of COVID-19 Vaccines with a marketing authorisation

COVID-19 vaccines are indicated for active immunisation to prevent COVID-19 disease caused by the SARS-CoV-2 virus.

Name De­scrip­tion Mar­ket­ing Au­tho­ri­sa­tion Hold­er Kind of Vac­cine Li­cense Num­ber Li­cense Date Further Information

Comir­naty

COVID-19-Impf­stoff (mR­NA)

Ver­wen­dung ab einem Leben­salter von 5-11 Jahren (10 µg) / Use from 5-11 years of age on­wards (10 µg)

Ver­wen­dung ab einem Leben­salter von 12 Jahren (30 µg) / Use from 12 years of age on­wards (30 µg)

BioN­Tech Man­u­fac­tur­ing GmbH

Mono EU/1/20/1528 21.12.2020

EPAR: Comir­naty

Pro­duk­t­in­for­ma­tion: Comir­naty (ein­schl. Impf­stoff­for­mulierung für Kinder von 5-11 Jahren ab Seite 42)

Prod­uct In­for­ma­tion: Comir­naty (in­cl. vac­cine for­mu­la­tion for chil­dren aged 5-11 years from page 39)

An­wen­dung von Comir­naty für 5- bis 11-jährige Kinder – wichtige Hin­weise für Ärztin­nen und Ärzte

Use of Comir­naty for 5- to 11-Year-Old Chil­dren - Im­por­tant In­for­ma­tion for Med­i­cal Doc­tors

Rote-Hand-Brief: BioN­Tech und Mod­er­na zu den Impf­stof­fen Comir­naty und Spike­vax (19.07.2021)

COVID-19 Vac­cine Janssen

COVID-19-Impf­stoff (Vek­tor-Impf­stoff)

Ver­wen­dung ab einem Leben­salter von 18 Jahren / Use from 18 years of age on­wards

Janssen-Cilag In­ter­na­tion­al NV

Mono EU/1/20/1525 11.03.2021

EPAR: COVID-19 Vac­cine Janssen

Pro­duk­t­in­for­ma­tion: COVID-19 Vac­cine Janssen

Prod­uct In­for­ma­tion: COVID-19 Vac­cine Janssen

Rote-Hand-Brief: COVID-19 Vac­cine Janssen (13.10.2021)

Rote-Hand-Brief: COVID-19 Vac­cine Janssen (19.07.2021)

Rote-Hand-Brief: COVID-19 Vac­cine Janssen (26.04.2021)

Nu­vax­ovid (NVX-CoV2373)

COVID-19-Impf­stoff (Pro­tein­basiert­er Impf­stoff)

Ver­wen­dung ab einem Leben­salter von 18 Jahren / Use from 18 years of age on­wards

No­vavax CZ a.s.

Mono EU/1/21/1618 20.12.2021

EPAR: Nu­vax­ovid

Pro­duk­t­in­for­ma­tion: Nu­vax­ovid

Prod­uct In­for­ma­tion: Nu­vax­ovid

Spike­vax (COVID-19 Vac­cine Mod­er­na)

COVID-19-Impf­stoff (mR­NA)

Ver­wen­dung ab einem Leben­salter von 12 Jahren / Use from 12 years of age on­wards

Mod­er­na Biotech Spain, S.L.

Mono EU/1/20/1507 06.01.2021

EPAR: Spike­vax (COVID-19 Vac­cine Mod­er­na)

Pro­duk­t­in­for­ma­tion: Spike­vax (COVID-19 Vac­cine Mod­er­na)

Prod­uct In­for­ma­tion: Spike­vax (COVID-19 Vac­cine Mod­er­na)

Rote-Hand-Brief: BioN­Tech und Mod­er­na zu den Impf­stof­fen Comir­naty und Spike­vax (19.07.2021)

Vaxzevria (COVID-19 Vac­cine As­traZeneca)

COVID-19-Impf­stoff (Vek­tor-Impf­stoff)

Ver­wen­dung ab einem Leben­salter von 18 Jahren / Use from 18 years of age on­wards

As­traZeneca AB, Schwe­den

Mono EU/1/21/1529 29.01.2021

EPAR: Vaxzevria (COVID-19 Vac­cine As­traZeneca)

Pro­duk­t­in­for­ma­tion: Vaxzevria (COVID-19 Vac­cine As­traZeneca)

Prod­uct In­for­ma­tion: Vaxzevria (COVID-19 Vac­cine As­traZeneca)

Rote-Hand-Brief: Vaxzevria / COVID-19 Vac­cine As­traZeneca (13.10.2021)

Rote-Hand-Brief: Vaxzevria / COVID-19 Vac­cine As­traZeneca (23.06.2021)

Rote-Hand-Brief: Vaxzevria / COVID-19 Vac­cine As­traZeneca (02.06.2021)

Rote-Hand-Brief: Vaxzevria / COVID-19 Vac­cine As­traZeneca (13.04.2021)

Rote-Hand-Brief: COVID-19 Vac­cine As­traZeneca (24.03.2021)

19.03.2021: In­for­ma­tion für Ärztin­nen und Ärzte - COVID-19-Impf­stoff As­traZeneca

19.03.2021: In­for­ma­tion for Physi­cians - COVID-19 Vac­cine As­traZeneca

Disclaimer

The vaccine list contains the preparations that have a valid authorisation from the European Commission. It does not provide any information about whether the preparations are available on the market.

Updated: 21.01.2022